Hemispherian Starts Phase 1/2a Trial of GLIX1 Hemispherian started a Phase 1/2a GLIX1 trial on Apr 8, 2026; glioblastoma median OS is 12–15 months and 5-year survival ~7%, underscoring high unmet need.

Hemispherian Starts Phase 1/2a Trial of GLIX1: Hemispherian started a Phase 1/2a GLIX1 trial on Apr 8, 2026; glioblastoma median OS is 12–15 months and 5-year survival ~7%, underscoring high unmet need. 👈 Read full analysis #Hemispherian #GLIX1Trial #Glioblastoma #CancerResearch #ClinicalTrials